Results · Apr-Jun 2026
Venmax Drugs And Pharmaceuticals Q1 FY27 results
Sales grew 105% to ₹2.5 crore from ₹1.2 crore in Apr-Jun 2025.
Operating profit grew 205% to ₹0.12 crore, an operating margin of 4.7% (up 1.6 points from a year ago).
Net profit grew 212% to ₹0.12 crore from ₹0.04 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −37%, net profit +9%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2.5 | 1.2 | +105% |
| Operating profit (EBITDA) | 0.1 | 0.0 | +205% |
| Operating margin | 4.7% | 3.2% | +1.6 pts |
| Net profit | 0.1 | 0.0 | +212% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.